MARKET

HALO

HALO

Halozyme Thrp
NASDAQ

Real-time Quotes | Nasdaq Last Sale

45.09
+0.76
+1.71%
Opening 15:39 05/24 EDT
OPEN
44.06
PREV CLOSE
44.33
HIGH
45.14
LOW
43.78
VOLUME
454.71K
TURNOVER
12.98M
52 WEEK HIGH
46.62
52 WEEK LOW
31.36
MARKET CAP
6.22B
P/E (TTM)
15.11
1D
5D
1M
3M
1Y
5Y
Cannabis Movers & Shakers: Mind Medicine, 22nd Century Group, Grown Rogue International
Mind Medicine Names New CEO Mind Medicine Inc. (NASDAQ: MNMD) (NEO: MMED) has hired Schond L. Greenway to oversee its finance department.
Benzinga · 7h ago
MindMed Appoints Schond L. Greenway As CFO
Mind Medicine Inc. (NASDAQ: MNMD), (NEO:MMED), a clinical stage bio-pharmaceutical company developing novel products to treat brain health disorders, appointed Schond L. Greenway as CFO.
Benzinga · 1d ago
Endo (ENDP) Crashes 46.54% as it Looks to Restructure Debt
Endo (ENDP) plunges on reports of negotiations with its lenders and senior bondholders about a possible restructuring of more than $8 billion of debt.
Zacks · 5d ago
5 Reasons Why You Should Add Halozyme (HALO) to Your Portfolio
We provide five reasons, which make Halozyme (HALO) a good investment option in 2022.
Zacks · 5d ago
Community Health (CYH) Boosts Obstetrics Care With Technology
Community Health (CYH) employs PeriGen's technology to bring about enhanced obstetrics services and assure the safety of mothers as well as babies in the labor and delivery procedures.
Zacks · 05/17 14:44
Is Galapagos (GLPG) Outperforming Other Medical Stocks This Year?
Here is how Galapagos NV (GLPG) and Halozyme Therapeutics (HALO) have performed compared to their sector so far this year.
Zacks · 05/16 13:40
Is Halozyme Therapeutics (HALO) a Smart Long-Term Buy?
Bernzott Capital Advisors, an investment management firm, published its “US Small Cap Value Fund” first quarter 2022 investor letter – a copy of which can be downloaded here. The portfolio fell -4.6% (gross), modestly below the Russell 2000 Value’s decline...
Insider Monkey · 05/12 13:26
Halozyme (HALO) Q1 Earnings Miss, Royalties Aid Y/Y Revenues
Halozyme (HALO) first-quarter earnings and sales miss estimates. Strong demand for the partnered drug, subcutaneous Darzalex, boosts the top line.
Zacks · 05/11 13:36
More
No Data
Learn about the latest financial forecast of HALO. Analyze the recent business situations of Halozyme Thrp through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 9 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

0.00%Strong Buy
77.78%Buy
11.11%Hold
0.00%Under-perform
11.11%Sell
Analyst Price Target
The average HALO stock price target is 48.57 with a high estimate of 62.00 and a low estimate of 19.00.
High62.00
Average48.57
Low19.00
Current 44.82
EPS
Actual
Estimate
0.170.330.490.66
Q2 2021
Q3 2021
Q4 2021
Q1 2022
Q2 2022
Institutional Holdings
Institutions: 431
Institutional Holdings: 151.27M
% Owned: 109.65%
Shares Outstanding: 137.95M
TypeInstitutionsShares
Increased
106
3.57M
New
33
1.98M
Decreased
120
5.36M
Sold Out
35
1.38M
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-2.05%
Pharmaceuticals & Medical Research
+0.25%
Key Executives
Non-Executive Chairman/Independent Director
Connie Matsui
President/Chief Executive Officer/Director
Helen Torley
Chief Financial Officer/Senior Vice President
Nicole Labrosse
Senior Vice President/Chief Technology Officer
Michael Labarre
Senior Vice President/Chief Compliance Officer/General Counsel/Secretary
Mark Snyder
Independent Director
Jean-Pierre Bizzari
Independent Director
Bernadette Connaughton
Independent Director
James Daly
Independent Director
Jeffrey Henderson
Independent Director
Moni Miyashita
Independent Director
Matthew Posard
No Data
No Data
About HALO
Halozyme Therapeutics, Inc. is a biopharma technology platform company. The Company licenses its technology to biopharmaceutical companies to collaboratively develop products that combine its ENHANZE drug delivery technology with the collaborators' compounds. The Company's lead enzyme, rHuPH20, is used to facilitate the delivery of injected drugs and fluids. The Company's approved product and its collaborators’ approved products and product candidates are based on rHuPH20, a patented recombinant human hyaluronidase enzyme. The Company's lead product, Hylenex recombinant, is a formulation of rHuPH20 that facilitates subcutaneous fluid administration for achieving hydration, to increase the dispersion and absorption of other injected drugs and, in subcutaneous urography, to improve resorption of radiopaque agents. Its pipeline products include Herceptin SC, HYQVIA, DARZALEX and others.

Webull offers kinds of Halozyme Therapeutics, Inc. stock information, including NASDAQ:HALO real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, HALO stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading HALO stock methods without spending real money on the virtual paper trading platform.